{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:09:12Z","timestamp":1780074552122,"version":"3.54.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and purpose<\/jats:title>\n                <jats:p>Spinal muscular atrophy (SMA) as the second most common neurodegenerative disorder in childhood is characterized by the deficiency of survival of motor neuron (<jats:italic>SMN<\/jats:italic>) protein leading predominantly to degeneration of alpha motor neurons and consequently to progressive muscle weakness and atrophy. Besides some biomarkers like <jats:italic>SMN2<\/jats:italic> copy number therapeutic biomarkers for SMA with known relevance for neuromuscular transmission are lacking. Here, we examined the potential of Thrombospondin-4 (TSP4) to serve as a cerebrospinal fluid (CSF) biomarker, which may also indicate treatment response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used untargeted proteomic analyses to determine biomarkers in CSF samples derived from pediatric pre-symptomatic (<jats:italic>n<\/jats:italic>\u2009=\u20096) and symptomatic (<jats:italic>n<\/jats:italic>\u2009=\u20094) SMA patients. The identified biomarker TSP4 was then validated in additional 68 CSF samples (9 adult and 24 pediatric SMA patients, 5 adult and 13 pediatric non-disease controls in addition to 17 pediatric disease controls) by enzyme-linked immunosorbent assay (ELISA) as an additional analytical approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Untargeted proteomic analyses of CSF identified a dysregulation of TSP4 and revealed a difference between pre-symptomatic SMA patients and patients identified after the onset of first symptoms. Subsequent ELISA-analyses showed that TSP4 is decreased in pediatric but not adult SMA patients. CSF of pediatric patients with other neurological disorders demonstrated no alteration of TSP4 levels. Furthermore, CSF TSP4 levels of pediatric SMA patients increased after first dose of Nusinersen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We found that TSP4 levels are exclusively reduced in CSF of pediatric SMA patients and increase after treatment, leading us to the hypothesis that TSP4 could serve as a CSF biomarker with the potential to monitor treatment response in pediatric SMA patients. Moreover, TSP4 enable to distinguish pre-symptomatic and symptomatic patients suggesting a potential to serve as a stratification marker.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12670-0","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:02:05Z","timestamp":1725602525000},"page":"7000-7011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9162-2517","authenticated-orcid":false,"given":"Vera","family":"Dobelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hentschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Della Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Isabell","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schara-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"K\u00f6lbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"12670_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC et al (2017) Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis 12:124","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"12670_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155\u2013165","journal-title":"Cell"},{"issue":"11","key":"12670_CR3","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96(11):6307\u20136311","journal-title":"Proc Natl Acad Sci USA"},{"key":"12670_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1242\/dmm.030148","volume":"10","author":"M Bowerman","year":"2017","unstructured":"Bowerman M et al (2017) Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech 10:943\u2013954","journal-title":"Dis Model Mech"},{"key":"12670_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/ng0797-265","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre S, Burlet P, Liu Q et al (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. https:\/\/doi.org\/10.1038\/ng0797-265","journal-title":"Nat Genet"},{"issue":"6","key":"12670_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/bpa.12071","volume":"23","author":"D Bottai","year":"2013","unstructured":"Bottai D, Adami R (2013) Spinal muscular atrophy: new findings for an old pathology. Brain Pathol 23(6):613\u2013622. https:\/\/doi.org\/10.1111\/bpa.12071. (Epub 2013 Jun 28)","journal-title":"Brain Pathol"},{"issue":"7","key":"12670_CR7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.2174\/15665240113139990044","volume":"13","author":"BB Goulet","year":"2013","unstructured":"Goulet BB, Kothary R, Parks RJ (2013) At the \u201cjunction\u201d of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression. Curr Mol Med 13(7):1160\u20131174. https:\/\/doi.org\/10.2174\/15665240113139990044","journal-title":"Curr Mol Med"},{"issue":"10","key":"12670_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.nmd.2017.07.007","volume":"27","author":"MC Pera","year":"2017","unstructured":"Pera MC, Luigetti M, Pane M et al (2017) 6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction. Neuromuscul Disord 27(10):879\u2013882. https:\/\/doi.org\/10.1016\/j.nmd.2017.07.007. (Epub 2017 Jul 14)","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"12670_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111393","volume":"40","author":"S Tisdale","year":"2022","unstructured":"Tisdale S, Van Alstyne M, Simon CM et al (2022) SMN controls neuromuscular junction integrity through U7 snRNP. Cell Rep 40(12):111393. https:\/\/doi.org\/10.1016\/j.celrep.2022.111393","journal-title":"Cell Rep"},{"key":"12670_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clinph.2023.06.024","volume":"154","author":"LE Habets","year":"2023","unstructured":"Habets LE, Bartels B, Jeneson JAL et al (2023) Enhanced low-threshold motor unit capacity during endurance tasks in patients with spinal muscular atrophy using pyridostigmine. Clin Neurophysiol 154:100\u2013106. https:\/\/doi.org\/10.1016\/j.clinph.2023.06.024. (Epub 2023 Jul 20)","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"12670_CR11","doi-asserted-by":"publisher","first-page":"fcac324","DOI":"10.1093\/braincomms\/fcac324","volume":"5","author":"M Stam","year":"2022","unstructured":"Stam M, Wijngaarde CA, Bartels B et al (2022) Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2\u20134. Brain Commun. 5(1):fcac324. https:\/\/doi.org\/10.1093\/braincomms\/fcac324","journal-title":"Brain Commun."},{"issue":"7","key":"12670_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","volume":"29","author":"AL Frongia","year":"2019","unstructured":"Frongia AL, Natera-de Benito D, Ortez C et al (2019) Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II. Neuromuscul Disord 29(7):517\u2013524. https:\/\/doi.org\/10.1016\/j.nmd.2019.04.003. (Epub 2019 Apr 18)","journal-title":"Neuromuscul Disord"},{"key":"12670_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","volume":"73","author":"S Khirani","year":"2017","unstructured":"Khirani S, Dabaj I, Amaddeo A et al (2017) Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy. Pediatr Neurol 73:78-87.e1. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.04.013. (Epub 2017 Apr 20)","journal-title":"Pediatr Neurol"},{"key":"12670_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbrep.2015.10.012","volume":"4","author":"NIF Harahap","year":"2015","unstructured":"Harahap NIF, Nurputra DK, Ar Rochmah M et al (2015) Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells. Biochem Biophys Rep 4:351\u2013356. https:\/\/doi.org\/10.1016\/j.bbrep.2015.10.012","journal-title":"Biochem Biophys Rep"},{"issue":"12","key":"12670_CR15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmg.2010.080366","volume":"47","author":"FD Tiziano","year":"2010","unstructured":"Tiziano FD, Lomastro R, Pinto AM et al (2010) Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet 47(12):856\u2013858. https:\/\/doi.org\/10.1136\/jmg.2010.080366. (Epub 2010 Sep 12)","journal-title":"J Med Genet"},{"issue":"1","key":"12670_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jmg.2007.051177","volume":"45","author":"C Angelozzi","year":"2008","unstructured":"Angelozzi C, Borgo F, Tiziano FD et al (2008) Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 45(1):29\u201331. https:\/\/doi.org\/10.1136\/jmg.2007.051177. (Epub 2007 Oct 11)","journal-title":"J Med Genet"},{"issue":"11","key":"12670_CR17","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1007\/s00415-022-11231-7","volume":"269","author":"S Bonanno","year":"2022","unstructured":"Bonanno S, Giossi R, Zanin R et al (2022) Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial. J Neurol 269(11):5858\u20135867. https:\/\/doi.org\/10.1007\/s00415-022-11231-7. (Epub 2022 Jun 28)","journal-title":"J Neurol"},{"key":"12670_CR18","doi-asserted-by":"publisher","unstructured":"Mercuri E, Deconinck N, Mazzone ES, et al. SUNFISH Study Group. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7. (Erratum in: Lancet Neurol. 2022 Feb;21(2):e2. Erratum in: Lancet Neurol. 2022 Mar;21(3):e3. Erratum in: Lancet Neurol. 2022 May;21(5):e5).","DOI":"10.1016\/S1474-4422(21)00367-7"},{"issue":"4","key":"12670_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA et al (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20(4):284\u2013293. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6. (Epub 2021 Mar 17)","journal-title":"Lancet Neurol"},{"key":"12670_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"key":"12670_CR21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1710504","journal-title":"N Engl J Med"},{"key":"12670_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00207454.2023.2251662","volume":"1","author":"Y Tachibana","year":"2023","unstructured":"Tachibana Y, Sato R, Makioka H et al (2023) Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan. Int J Neurosci 1:1. https:\/\/doi.org\/10.1080\/00207454.2023.2251662. (Epub ahead of print)","journal-title":"Int J Neurosci"},{"issue":"4","key":"12670_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00115-018-0653-7","volume":"90","author":"MC Walter","year":"2019","unstructured":"Walter MC, Dr\u00e4ger B, G\u00fcnther R et al (2019) Treatment evaluation in patients with 5q-associated spinal muscular atrophy: real-world experience. Nervenarzt 90(4):343\u2013351","journal-title":"Nervenarzt"},{"issue":"3","key":"12670_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","volume":"86","author":"M Pane","year":"2019","unstructured":"Pane M, Coratti G, Sansone VA et al (2019) Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data. Ann Neurol 86(3):443\u2013451","journal-title":"Ann Neurol"},{"key":"12670_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/B978-0-12-803685-3.00024-0","volume-title":"Spinal muscular atrophy: disease mechanisms and therapy","author":"WD Arnold","year":"2017","unstructured":"Arnold WD, Simard LR, Rutkove SB, Kolb SJ (2017) Development and testing of biomarkers in spinal muscular atrophy. In: Sumner CJ, Paushkin S, Ko C-P (eds) Spinal muscular atrophy: disease mechanisms and therapy, 1st edn. Academic Press, Cambridge, pp 383\u2013397","edition":"1"},{"issue":"5","key":"12670_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras BT, Crawford TO, Finkel RS et al (2019) Neurofilament as a poten-tial biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 6(5):932\u2013944","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"12670_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S et al (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J Neuromuscul Dis 6(4):453\u2013465. https:\/\/doi.org\/10.3233\/JND-190416","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"12670_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128560","volume":"10","author":"V Valsecchi","year":"2015","unstructured":"Valsecchi V, Boido M, De Amicis E et al (2015) Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model. PLoS ONE 10(6):e0128560. https:\/\/doi.org\/10.1371\/journal.pone.0128560","journal-title":"PLoS ONE"},{"issue":"3","key":"12670_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/0960-9822(93)90270-x","volume":"3","author":"J Adams","year":"1993","unstructured":"Adams J, Lawler J (1993) Extracellular matrix: the thrombospondin family. Curr Biol 3(3):188\u2013190. https:\/\/doi.org\/10.1016\/0960-9822(93)90270-x","journal-title":"Curr Biol"},{"issue":"3\u20134","key":"12670_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12079-009-0060-8","volume":"3","author":"P Bornstein","year":"2009","unstructured":"Bornstein P (2009) Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal 3(3\u20134):189\u2013200. https:\/\/doi.org\/10.1007\/s12079-009-0060-8. (Epub 2009 Oct 2)","journal-title":"J Cell Commun Signal"},{"key":"12670_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev.cellbio.17.1.25","volume":"17","author":"JC Adams","year":"2001","unstructured":"Adams JC (2001) Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 17:25\u201351. https:\/\/doi.org\/10.1146\/annurev.cellbio.17.1.25","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"6","key":"12670_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.biocel.2004.01.004","volume":"36","author":"JC Adams","year":"2004","unstructured":"Adams JC, Lawler J (2004) The thrombospondins. Int J Biochem Cell Biol 36(6):961\u2013968. https:\/\/doi.org\/10.1016\/j.biocel.2004.01.004","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"12670_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s00018-007-7484-1","volume":"65","author":"CB Carlson","year":"2008","unstructured":"Carlson CB, Lawler J, Mosher DF (2008) Structures of thrombospondins. Cell Mol Life Sci 65(5):672\u2013686. https:\/\/doi.org\/10.1007\/s00018-007-7484-1","journal-title":"Cell Mol Life Sci"},{"key":"12670_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1083\/jcb.120.4.1059","volume":"120","author":"J Lawler","year":"1993","unstructured":"Lawler J, Duquette M, Whittaker CA et al (1993) Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. J Cell Biol 120:1059\u20131067","journal-title":"J Cell Biol"},{"issue":"26","key":"12670_CR35","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1523\/JNEUROSCI.6494-11.2012","volume":"32","author":"DS Kim","year":"2012","unstructured":"Kim DS, Li KW, Boroujerdi A et al (2012) Thrombospondin-4 contributes to spinal sensitization and neuropathic pain states. J Neurosci 32(26):8977\u20138987. https:\/\/doi.org\/10.1523\/JNEUROSCI.6494-11.2012","journal-title":"J Neurosci"},{"issue":"4","key":"12670_CR36","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1083\/jcb.131.4.1083","volume":"131","author":"S Arber","year":"1995","unstructured":"Arber S, Caroni P (1995) Thrombospondin-4, an extracellular matrix protein expressed in the developing and adult nervous system promotes neurite outgrowth. J Cell Biol 131(4):1083\u20131094. https:\/\/doi.org\/10.1083\/jcb.131.4.1083","journal-title":"J Cell Biol"},{"issue":"1","key":"12670_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","volume":"16","author":"K Vill","year":"2021","unstructured":"Vill K, Schwartz O, Blaschek A, Gl\u00e4ser D, Nennstiel U, Wirth B, Burggraf S, R\u00f6schinger W, Becker M, Czibere L, Durner J, Eggermann K, Olgem\u00f6ller B, Harms E, Schara U, K\u00f6lbel H, M\u00fcller-Felber W (2021) Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis 16(1):153. https:\/\/doi.org\/10.1186\/s13023-021-01783-8","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"12670_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00401-024-02709-x","volume":"147","author":"A Roos","year":"2024","unstructured":"Roos A, Schmitt LI, Hansmann C, Hezel S, Salmanian S, Hentschel A, Meyer N, Marina AD, K\u00f6lbel H, Kleinschnitz C, Schara-Schmidt U, Leo M, Hagenacker T (2024) Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy. Acta Neuropathol 147(1):53. https:\/\/doi.org\/10.1007\/s00401-024-02709-x","journal-title":"Acta Neuropathol"},{"issue":"7","key":"12670_CR39","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/ene.15331","volume":"29","author":"DC Schorling","year":"2022","unstructured":"Schorling DC, K\u00f6lbel H, Hentschel A et al (2022) Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy. Eur J Neurol 29(7):2084\u20132096. https:\/\/doi.org\/10.1111\/ene.15331","journal-title":"Eur J Neurol"},{"issue":"Suppl","key":"12670_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0092-8674(05)80031-5","volume":"72","author":"ZW Hall","year":"1993","unstructured":"Hall ZW, Sanes JR (1993) Synaptic structure and development: the neuromuscular junction. Cell 72(Suppl):99\u2013121. https:\/\/doi.org\/10.1016\/s0092-8674(05)80031-5","journal-title":"Cell"},{"issue":"3","key":"12670_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.matbio.2012.01.004","volume":"31","author":"WC Risher","year":"2012","unstructured":"Risher WC, Eroglu C (2012) Thrombospondins as key regulators of synaptogenesis in the central nervous system. Matrix Biol 31(3):170\u2013177. https:\/\/doi.org\/10.1016\/j.matbio.2012.01.004. (Epub 2012 Jan 21)","journal-title":"Matrix Biol"},{"issue":"1","key":"12670_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/jcp.26877","volume":"234","author":"W Qian","year":"2018","unstructured":"Qian W, Li N, Cao Q, Fan J (2018) Thrombospondin-4 critically controls transforming growth factor \u03b21 induced hypertrophic scar formation. J Cell Physiol 234(1):731\u2013739. https:\/\/doi.org\/10.1002\/jcp.26877. (Epub 2018 Aug 21)","journal-title":"J Cell Physiol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12670-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12670-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12670-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T03:55:19Z","timestamp":1727927719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12670-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["12670"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12670-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}